Leerink Partnrs Issues Negative Estimate for CRSP Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Equities research analysts at Leerink Partnrs dropped their Q2 2025 earnings per share estimates for CRISPR Therapeutics in a research report issued on Monday, May 19th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn ($1.74) per share for the quarter, down from their prior forecast of ($1.45). The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share. Leerink Partnrs also issued estimates for CRISPR Therapeutics' Q3 2025 earnings at ($1.55) EPS, Q4 2025 earnings at ($1.35) EPS and FY2025 earnings at ($6.21) EPS.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. The business's revenue was up 71.6% on a year-over-year basis. During the same period in the previous year, the business posted ($1.43) earnings per share.

A number of other research firms also recently commented on CRSP. TD Cowen raised shares of CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 target price for the company in a research report on Wednesday, February 12th. The Goldman Sachs Group dropped their price target on CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating on the stock in a research note on Thursday, May 8th. Chardan Capital reduced their price objective on CRISPR Therapeutics from $84.00 to $82.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Morgan Stanley increased their target price on CRISPR Therapeutics from $30.00 to $32.00 and gave the company an "underweight" rating in a report on Friday, February 14th. Finally, JMP Securities restated a "market outperform" rating and set a $86.00 price target on shares of CRISPR Therapeutics in a research note on Wednesday. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, CRISPR Therapeutics currently has a consensus rating of "Hold" and an average price target of $71.75.

CRISPR Therapeutics Stock Down 5.8%

CRSP opened at $36.99 on Thursday. The stock has a market capitalization of $3.19 billion, a price-to-earnings ratio of -8.46 and a beta of 1.88. The firm has a 50 day moving average price of $37.24 and a 200-day moving average price of $42.19. CRISPR Therapeutics has a twelve month low of $30.04 and a twelve month high of $67.88.

Institutional Trading of CRISPR Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Magnetar Financial LLC bought a new stake in shares of CRISPR Therapeutics during the fourth quarter valued at approximately $359,000. Baker BROS. Advisors LP increased its holdings in CRISPR Therapeutics by 55.1% in the 4th quarter. Baker BROS. Advisors LP now owns 1,308,011 shares of the company's stock valued at $51,483,000 after acquiring an additional 464,936 shares during the last quarter. Vanguard Group Inc. lifted its stake in CRISPR Therapeutics by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 1,735,998 shares of the company's stock worth $68,329,000 after purchasing an additional 10,579 shares in the last quarter. KBC Group NV boosted its holdings in shares of CRISPR Therapeutics by 2,047.4% during the 4th quarter. KBC Group NV now owns 60,514 shares of the company's stock valued at $2,382,000 after purchasing an additional 57,696 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of CRISPR Therapeutics during the fourth quarter valued at about $3,231,000. Institutional investors own 69.20% of the company's stock.

Insider Activity

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 9,973 shares of the stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $423,054.66. Following the completion of the sale, the chief executive officer now owns 180,890 shares in the company, valued at approximately $7,673,353.80. This represents a 5.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, General Counsel James R. Kasinger sold 2,850 shares of the company's stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $120,897.00. Following the completion of the transaction, the general counsel now directly owns 77,530 shares of the company's stock, valued at approximately $3,288,822.60. This trade represents a 3.55% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 14,021 shares of company stock valued at $594,771 in the last ninety days. Corporate insiders own 4.30% of the company's stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.